# Aurealis Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aurealis-therapeutics

- Industry: Biotechnology
- Headquarters: Zug, Switzerland
- Website: www.aurealistherapeutics.com
- Total disclosed funding: $24M
- Latest round: Series A (Mar 27, 2023)
- Investors on record: 6

## About

Based in Basel, Switzerland, and founded in 2015 by co-founders Ph.D. Thomas Wirth and Heinz List, Aurealis Therapeutics, formerly Aurealis Pharma operates as a Nordic cell and gene therapy platform company developing gene therapy drugs for chronic wounds and other inflammatory degenerative diseases. In November 2024, Aurealis Therapeutics raised CHF 8 million in venture funding from unspecified investors. Aurealis Therapeutics provides AUP-16 for chronic wounds patients and is under phase-1 trial for diabetic foot ulcer (DFU) patients. The company offers AUP-55 and AUP-65 for ovarian cancer and another secondary peritoneal carcinomatosis and is under pre-clinical trials. In addition, the firm provides AUP-18 and AUP-20 for inflammation therapy for its patients.

## Funding rounds

- Series A, Mar 27, 2023, $10M — Tesi, Zhejiang Huahai Pharmaceutical, Lynx Financial (HK) Ltd
- Series B, Feb 8, 2019, $7.8M — Finnvera, Business Finland
- Series A, Aug 25, 2017, $5.8M — Tekes Venture Capital, Finnvera

## Investors

- Tekes Venture Capital — Series A
- Finnvera (https://capitalatlas.ai/funds/finnvera) — Series A, Series B
- Business Finland — Series B
- Tesi (https://capitalatlas.ai/funds/tesi) — Series A
- Zhejiang Huahai Pharmaceutical — Series A
- Lynx Financial (HK) Ltd — Series A